Castle Biosciences (CSTL) Competitors $23.57 +1.29 (+5.79%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CSTL vs. HTFL, CELC, ADUS, LFST, PGNY, ARDT, PACS, NHC, VRDN, and AVAHShould you be buying Castle Biosciences stock or one of its competitors? The main competitors of Castle Biosciences include Heartflow (HTFL), Celcuity (CELC), Addus HomeCare (ADUS), LifeStance Health Group (LFST), Progyny (PGNY), Ardent Health (ARDT), PACS Group (PACS), National HealthCare (NHC), Viridian Therapeutics (VRDN), and Aveanna Healthcare (AVAH). These companies are all part of the "healthcare" industry. Castle Biosciences vs. Its Competitors Heartflow Celcuity Addus HomeCare LifeStance Health Group Progyny Ardent Health PACS Group National HealthCare Viridian Therapeutics Aveanna Healthcare Heartflow (NASDAQ:HTFL) and Castle Biosciences (NASDAQ:CSTL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation. Do analysts prefer HTFL or CSTL? Castle Biosciences has a consensus target price of $37.00, suggesting a potential upside of 56.98%. Given Castle Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Castle Biosciences is more favorable than Heartflow.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heartflow 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Castle Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor HTFL or CSTL? In the previous week, Castle Biosciences had 4 more articles in the media than Heartflow. MarketBeat recorded 7 mentions for Castle Biosciences and 3 mentions for Heartflow. Castle Biosciences' average media sentiment score of 1.08 beat Heartflow's score of 0.88 indicating that Castle Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heartflow 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Castle Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, HTFL or CSTL? Castle Biosciences has higher revenue and earnings than Heartflow. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHeartflowN/AN/AN/AN/AN/ACastle Biosciences$332.07M2.06$18.25M-$0.35-67.34 Is HTFL or CSTL more profitable? Heartflow has a net margin of 0.00% compared to Castle Biosciences' net margin of -2.73%. Castle Biosciences' return on equity of 2.37% beat Heartflow's return on equity.Company Net Margins Return on Equity Return on Assets HeartflowN/A N/A N/A Castle Biosciences -2.73%2.37%2.03% Do institutionals & insiders hold more shares of HTFL or CSTL? 92.6% of Castle Biosciences shares are held by institutional investors. 6.5% of Castle Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryCastle Biosciences beats Heartflow on 10 of the 11 factors compared between the two stocks. Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSTL vs. The Competition Export to ExcelMetricCastle BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$686.23M$3.06B$5.75B$9.85BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-67.5821.1531.3126.63Price / Sales2.06383.94459.79120.56Price / Cash21.7044.4437.7659.36Price / Book1.508.0810.026.70Net Income$18.25M-$54.08M$3.27B$265.68M7 Day Performance18.03%2.44%3.26%3.46%1 Month Performance44.34%3.56%4.45%1.11%1 Year Performance-17.67%18.78%44.34%24.00% Castle Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSTLCastle Biosciences2.4614 of 5 stars$23.57+5.8%$37.00+57.0%-24.3%$686.23M$332.07M-67.58540HTFLHeartflowN/A$29.84+2.3%N/AN/A$2.37BN/A0.00699CELCCelcuity1.0094 of 5 stars$49.25-6.0%$50.60+2.7%+195.4%$2.22BN/A-14.2840Gap UpADUSAddus HomeCare4.9072 of 5 stars$116.65-1.5%$138.38+18.6%-12.8%$2.18B$1.15B25.7549,703Positive NewsInsider TradeLFSTLifeStance Health Group3.1962 of 5 stars$5.39-2.9%$8.50+57.7%-12.4%$2.16B$1.25B-107.8010,218News CoveragePositive NewsPGNYProgyny2.3117 of 5 stars$23.14-1.7%$25.10+8.5%+6.6%$2.02B$1.17B39.22310Positive NewsAnalyst ForecastARDTArdent Health3.3081 of 5 stars$12.70-2.2%$19.56+54.1%-31.8%$1.86B$5.97B7.0124,900PACSPACS Group2.9329 of 5 stars$11.75-2.5%$33.33+183.7%-70.7%$1.84B$3.56B0.0032,433News CoverageUpcoming EarningsNHCNational HealthCareN/A$111.98-2.5%N/A-15.2%$1.74B$1.46B14.0312,400News CoveragePositive NewsVRDNViridian Therapeutics1.9251 of 5 stars$18.57-3.4%$37.78+103.4%+23.9%$1.57B$300K-4.8550News CoveragePositive NewsAnalyst ForecastAVAHAveanna Healthcare2.0307 of 5 stars$7.43-0.5%$7.50+0.9%+43.8%$1.56B$2.02B92.8833,500 Related Companies and Tools Related Companies Heartflow Alternatives Celcuity Alternatives Addus HomeCare Alternatives LifeStance Health Group Alternatives Progyny Alternatives Ardent Health Alternatives PACS Group Alternatives National HealthCare Alternatives Viridian Therapeutics Alternatives Aveanna Healthcare Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CSTL) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access